We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Kazia Therapeutics Limited (KZIA) ADR EACH REP 100 ORD SHS SPON

Sell:$0.36 Buy:$0.38 Change: $0.001 (0.27%)
Market closed |  Prices as at close on 22 April 2024 | Switch to live prices |
Sell:$0.36
Buy:$0.38
Change: $0.001 (0.27%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 22 April 2024 | Switch to live prices |
Sell:$0.36
Buy:$0.38
Change: $0.001 (0.27%)
Market closed |  Prices as at close on 22 April 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Kazia Therapeutics Limited is an oncology focused drug development company. The Company is engaged in the pharmaceutical research and development. Its lead program includes Paxalisib and EVT801. Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3), which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. EVT801 is an inhibitor of VEGFR3, a cellular receptor for VEGF. The Company’s drug candidates are designed to treat disease, such as brain cancer, renal cancer, and liver cancer.

Contact details

Address:
Three International Towers Level 24
, 300 Barangaroo Avenue
SYDNEY
2000
Australia
Telephone:
+61 (2) 94724100
Website:
https://www.kaziatherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
KZIA
ISIN:
US48669G1058
Market cap:
$9.91 million
Shares in issue:
228.03 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • John Friend
    Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
  • Karen Krumeich
    Chief Financial Officer
  • Lilischkis Kimberley
    Clinical & Regulatory Affairs Manager
  • Peng Leong
    Chief Business Officer
  • Stephen Palmer
    Program Director - Degenerative Diseases
  • Justine Stehn
    Director - ATM Program
  • Anna Sandham
    Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.